Synthio Labs Raises $5 Million to Transform Life Sciences Customer Engagement with Clinical Voice AI
核心洞察
Synthio Labs (搜索) secured $5 million in seed funding led by Elevation Capital (搜索) to develop clinical-grade voice AI technology for pharmaceutical customer engagement.
The company's AI operating system includes three platforms: Jarvis for field teams, Ather for omnichannel engagement, and Simulation Studio for creating digital twins of clinicians and patients.
Early adopters include several top 10 pharmaceutical companies, with one project demonstrating the platform's ability to reach 5,000 eczema (搜索) patients in 48 hours.
Synthio Labs (搜索), a clinical-grade voice AI company focused on transforming life sciences customer engagement, has raised $5 million in seed funding to build what it describes as the "voice AI operating system" for pharmaceutical companies. The round was led by Elevation Capital (搜索) with participation from 1984 Ventures (搜索), Peak XV Partners (搜索), Y Combinator (搜索), and strategic angels from the global healthcare and AI ecosystem.
The San Francisco-based startup addresses a significant challenge in pharmaceutical customer engagement, where companies spend over $30 billion annually to engage doctors and patients through largely manual, fragmented, and difficult-to-scale communication methods. According to the company, doctors are flooded with information while many patients lack regular support, leading to treatment drop-off rates of up to 50% in long-term illnesses.
Three-Platform AI Operating System
Synthio Labs (搜索) has developed an integrated AI operating system comprising three flagship platforms designed to automate compliant conversations and deliver consistent experiences to clinicians and patients:
Jarvis serves as a clinical-grade voice AI copilot specifically designed for pharmaceutical field teams, enabling them to engage more effectively with healthcare providers.
Ather functions as a multimodal AI engine that powers seamless omnichannel engagement with both physicians and patients across multiple communication channels.
Simulation Studio represents an advanced insight platform that generates high-fidelity digital twins of clinicians and patients for research and strategic purposes.
Together, these products help life sciences teams automate compliant conversations, capture structured intelligence at scale, and deliver human-grade experiences to every clinician and patient interaction.
Proven Market Traction
The company has already secured early adoption from several top 10 pharmaceutical companies and leading direct-to-consumer healthcare brands. In a notable deployment, Synthio's voice AI technology reached more than 5,000 eczema (搜索) patients within 48 hours, demonstrating its ability to scale personalized support rapidly.
Rafal Pielak, Founder and CEO of Soteri Skin (搜索), praised the platform's effectiveness: "They built a voice AI agent that engaged thousands of eczema (搜索) patients, completing 5,000 calls in just two days. The agent supported onboarding, screening, and patient assistance end-to-end, fully automating our feedback and review collection."
Leadership and Vision
The company was founded by Supreet Deshpande (CEO), Sahitya Sridhar (Chief Product Officer), and Rajashekar Vasantha (CTO), who bring extensive expertise across pharmaceutical strategy and advanced AI engineering from leadership roles at McKinsey (搜索), ZS Associates (搜索), Amazon (搜索), and Audible (搜索). The founders have previously led multi-million-dollar commercial programs for global life sciences companies and played key roles in developing foundational large language models and multi-agent voice systems.
"Beyond breakthrough medicines, the future of healthcare will depend on how we reach and support every clinician and patient who relies on them," said Deshpande. "At Synthio, we're building the AI infrastructure that makes that possible – intelligently, compliantly, and at scale."
Krishna Mehra, AI Partner at Elevation Capital (搜索), emphasized the market opportunity: "We believe Synthio Labs (搜索) is defining the next major Customer Engagement infrastructure for Life Sciences. Their Clinical-grade Voice AI platform unifies how pharma communicates – giving field teams a powerful voice companion, and giving physicians and patients instant, trusted, compliant answers 24/7."
Strategic Growth Plans
The $5 million in funding will be deployed to expand Synthio's engineering and product teams, scale enterprise deployments across the United States and Europe, and deepen partnerships with leading life sciences clients. The company aims to establish AI-driven engagement as the new standard for how pharmaceutical teams support clinicians and patients globally.
Sridhar outlined the company's consumer-focused approach: "We're designing products that make every conversation between pharma and their customers smarter, faster, and more meaningful. Healthcare is moving into a world of abundance. Our view is simple: bring consumer-grade experiences to pharma and empower the people delivering care."